

Binding **nomination**

In relation to the Extraordinary General Meeting of Shareholders of Koninklijke Philips N.V. (Royal Philips) to be held on October 19, 2018.

Nominee for appointment as member of the **Supervisory Board**

In accordance with Article 19, paragraph 2 of the Articles of Association of the company, the Supervisory Board nominates the following person for appointment as member of the Supervisory Board, at the Extraordinary General Meeting of Shareholders 2018 (which nomination is binding).

Marc Harrison (1964, American)

Dr. A. Marc Harrison was born in the United States (1964) and has the American nationality. He is currently President & Chief Executive Officer of Intermountain Healthcare, a not-for-profit health system based in Salt Lake City (Utah) and the largest healthcare provider in the Intermountain West. Under Dr. Harrison's leadership, Intermountain is transforming healthcare through best clinical and operational practices designed to advance its mission of helping people live the healthiest lives possible.

In his career Dr. Harrison has gathered in-depth knowledge of the health system and healthcare industries in North America as well as globally. His expertise will be invaluable, in particular in view of Philips' transformation to a company focused on healthcare technology.

A specialist in pediatric critical care, Dr. Harrison held leadership positions at Cleveland Clinic prior to joining Intermountain in 2016. He most recently served as Chief of International Business Development for Cleveland Clinic, developing and implementing their international strategy, and as CEO of Cleveland Clinic Abu Dhabi, where he oversaw the establishment of 12 Institutes, five centers of excellence, and more than 30 medical and surgical specialties. Dr. Harrison also served as Cleveland Clinic's Chief Medical Operations Officer, involving oversight of a broad range of clinical operations worldwide, and as Chairman of Pediatric Critical Care.

Dr. Harrison holds no shares in Royal Philips.

The Supervisory Board proposes to appoint Dr. Harrison as a member of the Supervisory Board per October 19, 2018. Members of the Supervisory Board may be (re-)appointed for the term of four years as laid down in the Articles of Association. In line with the Dutch Corporate Governance Code, Dr. Harrison's term of appointment will expire at the end of the Annual General Meeting of Shareholders to be held in 2022.

Amsterdam, August 2018

The Supervisory Board

